L. Dussen

发表

Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy

C. Hollak, R. Boot, J. Aerts, 2014, Journal of Inherited Metabolic Disease.

Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature

C. Hollak, L. Dussen, M. Biegstraaten, 2013, British journal of haematology.

e- Blood Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response

C. Hollak, P. Mistry, A. Tylki-Szymańska, 2011 .

Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4–5 years

J. Goldblatt, C. Hollak, M. Cappellini, 2012, British journal of haematology.

Evaluation of an imaging biomarker, Dixon quantitative chemical shift imaging, in Gaucher disease: lessons learned

A. Nederveen, C. Hollak, M. Maas, 2014, Journal of Inherited Metabolic Disease.

Imaging Skeletal Involvement in Gaucher Disease

T. Hangartner, M. Maas, L. Dussen, 2013 .

Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease.

J. M. Aerts, P. Lips, C. Hollak, 2011, The Journal of clinical endocrinology and metabolism.

Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease.

C. Hollak, D. Aviezer, M. Maas, 2013, Blood cells, molecules & diseases.

Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4–5 years

J. Goldblatt, C. Hollak, M. Cappellini, 2012, British journal of haematology.